Custodio Estefanía, López-Alcalde Jesús, Herrero Mercè, Bouza Carmen, Jimenez Carolina, Storcksdieck Genannt Bonsmann Stefan, Mouratidou Theodora, López-Cuadrado Teresa, Benito Agustin, Alvar Jorge
European Commission, Joint Research Centre (JRC), Ispra, Italy.
Cochrane Database Syst Rev. 2018 Mar 26;3(3):CD012261. doi: 10.1002/14651858.CD012261.pub2.
Visceral leishmaniasis (VL) is a disease caused by a parasite, which can lead to death if untreated. Poor nutritional status hastens the progression of VL infection, and VL worsens malnutrition status. Malnutrition is one of the poor prognostic factors identified for leishmaniasis. However, the effects of nutritional supplementation in people treated for VL are not known.
To assess the effects of oral nutritional supplements in people being treated with anti-leishmanial drug therapy for VL.
We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register, CENTRAL, MEDLINE, Embase, LILACS, and two trial registers up to 12 September 2017. We checked conference proceedings and WHO consultative meeting reports, the reference lists of key documents and existing reviews, and contacted experts and nutritional supplement companies.
Randomized controlled trials (RCTs), quasi-randomized controlled trials (quasi-RCTs), and non-randomized controlled trials (NRCTs) of any oral nutritional supplement, compared to no nutritional intervention, placebo, or dietary advice alone, in people being treated for VL.
Two review authors independently screened the literature search results for studies that met the inclusion criteria. We had planned for two review authors to independently extract data and assess the risk of bias of the included studies. We planned to follow the Cochrane standard methodological procedures for assessing risk of bias and analysing the data.
We identified no eligible studies for this review, either completed or ongoing.
AUTHORS' CONCLUSIONS: We found no studies, either completed or ongoing, that assessed the effects of oral nutritional supplements in people with VL who were being treated with anti-leishmanial drug therapy. Thus, we could not draw any conclusions on the impact of these interventions on primary cure of VL, definitive cure of VL, treatment completion, self-reported recovery from illness or resolution of symptoms, weight gain, increased skinfold thickness, other measures of lean or total mass, or growth in children.This absence of evidence should not be interpreted as evidence of no effect for nutritional supplements in people under VL treatment. It means that we did not identify research that fulfilled our review inclusion criteria.The effects of oral nutritional supplements in people with VL who are being treated with anti-leishmanial drug therapy have yet to be determined by rigorous experimental studies, such as cluster-randomized trials, that focus on outcomes relevant for patients.
内脏利什曼病(VL)是一种由寄生虫引起的疾病,若不治疗可导致死亡。营养不良状况会加速VL感染的进展,而VL会使营养不良状况恶化。营养不良是已确定的利什曼病不良预后因素之一。然而,营养补充对接受VL治疗的患者的影响尚不清楚。
评估口服营养补充剂对接受抗利什曼原虫药物治疗VL患者的影响。
我们检索了Cochrane传染病小组(CIDG)专业注册库、Cochrane系统评价数据库、医学期刊数据库、Embase数据库、拉丁美洲和加勒比卫生科学数据库以及两个试验注册库,检索截至2017年9月12日的文献。我们查阅了会议论文集和世界卫生组织咨询会议报告、关键文献和现有综述的参考文献列表,并联系了专家和营养补充剂公司。
任何口服营养补充剂的随机对照试验(RCT)、半随机对照试验(quasi - RCT)和非随机对照试验(NRCT),与未进行营养干预、安慰剂或仅给予饮食建议相比,用于接受VL治疗的患者。
两位综述作者独立筛选文献检索结果,以找出符合纳入标准的研究。我们原计划让两位综述作者独立提取数据并评估纳入研究的偏倚风险。我们计划遵循Cochrane评估偏倚风险和分析数据的标准方法程序。
我们未找到该综述的合格研究,无论是已完成的还是正在进行的。
我们未找到已完成或正在进行的研究来评估口服营养补充剂对接受抗利什曼原虫药物治疗的VL患者的影响。因此,我们无法就这些干预措施对VL的初治、根治、治疗完成、自我报告的疾病康复或症状缓解、体重增加、皮褶厚度增加、瘦体重或总体重的其他测量指标或儿童生长的影响得出任何结论。缺乏证据不应被解释为营养补充剂对接受VL治疗的患者没有效果的证据。这意味着我们未找到符合我们综述纳入标准的研究。口服营养补充剂对接受抗利什曼原虫药物治疗的VL患者的影响尚未通过严格的实验研究确定,如关注与患者相关结局的整群随机试验。